Your browser doesn't support javascript.
loading
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.
Blagojevic, J; Bellando-Randone, S; Abignano, G; Avouac, J; Cometi, L; Czirják, L; Denton, C P; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, V K; Lóránd, V; Maurer, B; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, I H; Vettori, S; Walker, U A; Allanore, Y; Müller-Ladner, U; Del Galdo, F; Matucci-Cerinic, M.
Affiliation
  • Blagojevic J; Department of Experimental and Clinical Medicine, University of Florence, and Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, Villa Monna Tessa, viale Pieraccini 18, 50139, Florence, Italy. jelena308@hotmail.com.
  • Bellando-Randone S; Department of Experimental and Clinical Medicine, University of Florence, and Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, Villa Monna Tessa, viale Pieraccini 18, 50139, Florence, Italy.
  • Abignano G; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Avouac J; Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy.
  • Cometi L; Department of Rheumatology, University of Paris Descartes, Paris, France.
  • Czirják L; Department of Experimental and Clinical Medicine, University of Florence, and Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, Villa Monna Tessa, viale Pieraccini 18, 50139, Florence, Italy.
  • Denton CP; Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary.
  • Distler O; Department of Rheumatology, University College London, Royal Free Hospital, London, UK.
  • Frerix M; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
  • Guiducci S; Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik GmbH, Campus of the Justus-Liebig University Giessen, Bad Nauheim, Germany.
  • Huscher D; Department of Experimental and Clinical Medicine, University of Florence, and Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, Villa Monna Tessa, viale Pieraccini 18, 50139, Florence, Italy.
  • Jaeger VK; Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Lóránd V; Department of Rheumatology, University of Basel, Basel, Switzerland.
  • Maurer B; Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary.
  • Nihtyanova S; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
  • Riemekasten G; Department of Rheumatology, University College London, Royal Free Hospital, London, UK.
  • Siegert E; Clinic of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany.
  • Tarner IH; Department of Rheumatology and Clinical Immunology, Charité - Universitaetsmedizin Berlin, Corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Vettori S; Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik GmbH, Campus of the Justus-Liebig University Giessen, Bad Nauheim, Germany.
  • Walker UA; Rheumatology Section, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Allanore Y; Department of Rheumatology, University of Basel, Basel, Switzerland.
  • Müller-Ladner U; Department of Rheumatology, University of Paris Descartes, Paris, France.
  • Del Galdo F; Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik GmbH, Campus of the Justus-Liebig University Giessen, Bad Nauheim, Germany.
  • Matucci-Cerinic M; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Arthritis Res Ther ; 21(1): 35, 2019 01 24.
Article in En | MEDLINE | ID: mdl-30678703
ABSTRACT

BACKGROUND:

A consensus on digital ulcer (DU) definition in systemic sclerosis (SSc) has been recently reached (Suliman et al., J Scleroderma Relat Disord 2115-20, 2017), while for their evaluation, classification and categorisation, it is still missing. The aims of this study were to identify a set of essential items for digital ulcer (DU) evaluation, to assess if the existing DU classification was useful and feasible in clinical practice and to investigate if the new categorisation was preferred to the simple distinction of DU in recurrent and not recurrent, in patients with systemic sclerosis (SSc).

METHODS:

DeSScipher is the largest European multicentre study on SSc. It consists of five observational trials (OTs), and one of them, OT1, is focused on DU management. The DeSScipher OT1 items on DU that reached ≥ 60% of completion rate were administered to EUSTAR (European Scleroderma Trials and Research group) centres via online survey. Questions about feasibility and usefulness of the existing DU classification (DU due to digital pitting scars, to loss of tissue, derived from calcinosis and gangrene) and newly proposed categorisation (episodic, recurrent and chronic) were also asked.

RESULTS:

A total of 84/148 (56.8%) EUSTAR centres completed the questionnaire. DeSScipher items scored by ≥ 70% of the participants as essential and feasible for DU evaluation were the number of DU defined as a loss of tissue (level of agreement 92%), recurrent DU (84%) and number of new DU (74%). For 65% of the centres, the proposed classification of DU was considered useful and feasible in clinical practice. Moreover, 80% of the centres preferred the categorisation of DU in episodic, recurrent and chronic to simple distinction in recurrent/not recurrent DU.

CONCLUSIONS:

For clinical practice, EUSTAR centres identified only three essential items for DU evaluation and considered the proposed classification and categorisation as useful and feasible. The set of items needs to be validated while further implementation of DU classification and categorisation is warranted. TRIAL REGISTRATION Observational trial on DU (OT1) is one of the five trials of the DeSScipher project (ClinicalTrials.gov; OT1 Identifier NCT01836263 , posted on April 19, 2013).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Skin Ulcer / Fingers Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Arthritis Res Ther Journal subject: REUMATOLOGIA Year: 2019 Type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Skin Ulcer / Fingers Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Arthritis Res Ther Journal subject: REUMATOLOGIA Year: 2019 Type: Article Affiliation country: Italy